Cellerant Therapeutics, Inc.

UEI
LML1YE6L8KU3
CAGE
47BJ6
Primary NAICS
325414 Biological Product (except Diagnostic) Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
cellerant.com
Founded
2003
Employees
51-250
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells HHSN261201600043C National Cancer Institute (NIH) $1,496,276
Other function: development of IL1RAP antibodies targeting AML CS HHSN261201400030C National Cancer Institute (NIH) $223,524
Other functions - r & d biomedical (basic research) HHSN261201200076C National Cancer Institute (NIH) $194,467
Advanced development of therapeutics for treating neutropenia resulting from acute exposure to ionizing radiation can… HHSO100201000051C Office of the Assistant Secretary for Preparedness and Response $169,931,988
Develop therapy for hematopoetic syndrome resulting from acute radiation exposure HHSO100200800063C Office of the Assistant Secretary for Preparedness and Response $11,877,128

Grant awards

Award Agency Obligated Awarded
Novel indication for myeloid progenitor use: induction of tolerance R41AI108016 National Institutes of Health $200,787
Novel indication for myeloid progenitor use: induction of tolerance in solid organ transplantation R42AI108016 National Institute of Allergy and Infectious Diseases (NIH) $842,489
Non-clinical safety evaluation of myeloid progenitors W9113M0710002 Department of the Army $2,258,400
Development of EX vivo expanded megakaryocyte progenitors for platelet recovery f RC1AI080314 National Institutes of Health $1,000,000
Attenuation of radiation-induced GI injury by cultured myeloid progenitors R41CA126604 National Institutes of Health $300,000

Latest 5 listed here. See the rest on GovTribe.

Quick answers

Is Cellerant Therapeutics, Inc. registered in SAM.gov?

Cellerant Therapeutics, Inc.'s SAM.gov registration expired on March 6, 2021.

What is Cellerant Therapeutics, Inc.'s most recent federal award?

Cellerant Therapeutics, Inc.'s most recent federal contract award is Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells (HHSN261201600043C), from National Cancer Institute (NIH), on September 19, 2016.

On GovTribe

See Cellerant Therapeutics, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login